Table 4 Baseline HPV PCR and HRA results of patients enrolled
Variable | HIV-MSM vaccine (n = 66) | HIV-MSM placebo (n = 63) | p* |
|---|---|---|---|
PCR of HPV | |||
LR-HPV, n (%) | 39 (59) | 34 (53.9) | 0.63 |
HR-HPV, n (%) | 46 (69.7) | 44 (69.8) | 0.87 |
HR and LR HPV, n (%) | 28 (42.4) | 31 (49.2) | 0.39 |
Number of HR-HPV (IQR) | 1 (0–2) | 2 (0–3) | 0.22 |
Number of LR-HPV (IQR) | 1 (0–2) | 1 (0–2) | 0.94 |
Genotypes, n (%) | |||
HPV6 | 11 (16.6) | 8 (12.6) | 0.55 |
HPV11 | 8 (12.1) | 7 (11.1) | 0.88 |
HPV16 | 15 (22.7) | 15 (23.8) | 0.85 |
HPV16 species | 22 (33.3) | 24 (38.1) | 0.49 |
HPV18 | 4 (6.1) | 5 (7.9) | 0.74 |
HPV18 species | 18 (27.3) | 22 (34.9) | 0.35 |
Cytology, n (%) | |||
Normal | 26 (39.4) | 27 (42.9) | 0.69 |
LSIL | 34 (51.5) | 26 (41.3) | 0.24 |
HSIL | 1 (1.5) | 4 (6.3) | 0.21 |
ASC | 5 (7.6) | 6 (9.5) | 0.69 |
HRA, n (%) | |||
Normal | 33 (0.5) | 29 (46) | 0.65 |
LSIL | 33 (0.5) | 34 (53.9) | 0.65 |